GlobeNewswire·Apr 27, 2026, 7:00 AM ET

Altimmune Announces Closing of $225 Million Oversubscribed Public Offering of Securities

Altimmune raised $225 million in gross proceeds at closing, with an additional $225 million warrant tranche available.
Financing was led by Deep Track Capital alongside participation from TCGX, Viking Global Investors, RA Capital Management, & other investors.
Funds will support operations through the anticipated 52-week data readout of the Phase 3 MASH trial for pemvidutide.
The company expects to initiate the Phase 3 trial in the second half of 2026.
The offering consisted of 64,250,000 common shares & 64,250,000 accompanying warrants, plus up to 10,750,000 pre-funded warrants & accompanying warrants.
The combined offering price was $3.00 per common share & warrant, & $2.999 per pre-funded warrant & warrant.
Accompanying common stock warrants are immediately exercisable & expire on the fifth anniversary or 45 days after a successful Phase 3 data announcement.
Leerink Partners & Barclays served as joint bookrunning managers, while Titan Partners acted as co-bookrunning manager.
Shares were issued under two effective Form S-3 shelf registration statements filed in 2025 & a related Rule 462(b) filing made on April 22, 2026.